8-K: NovaBay Pharmaceuticals Accepts Revised PRN Offer, Increasing Purchase Price to $11.5 Million

NovaBay Pharmaceuticals has accepted a revised offer from PRN Physician Recommended Nutriceuticals, increasing the purchase price for its eyecare business to $11.5 million and entering into an amendment to the asset purchase agreement.

Summary

• NovaBay Pharmaceuticals has agreed to a revised offer from PRN Physician Recommended Nutriceuticals, increasing the base purchase price for its eyecare business to $11.5 million from the original $9.5 million.
• The company has entered into an amendment to the asset purchase agreement with PRN, which includes the removal of debt financing contingencies and a new representation from PRN that it has sufficient funding for the purchase price.
• PRN will provide NovaBay with a secured promissory note for up to $1.0 million, to be funded in two installments of $0.5 million each, which will be repaid upon closing of the transaction.
• PRN has also provided an equity funding commitment letter for up to $13.0 million to be used by PRN's parent company and contributed to PRN for payment of the purchase price.
• The NovaBay Board of Directors determined that a previous unsolicited offer from Refresh Acquisitions BidCo LLC was no longer a superior proposal after considering the revised terms from PRN.
• The special meeting of stockholders to approve the transaction with PRN is scheduled for November 22, 2024.
• The Board continues to recommend that stockholders approve the transaction with PRN and the potential voluntary liquidation and dissolution of the company.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the increased purchase price and the commitment from PRN. However, there are still risks associated with the transaction, such as the need for stockholder approval and the potential for delays, which temper the overall sentiment.

Positives

• The increased purchase price of $11.5 million provides additional value to NovaBay's stockholders.
• The removal of debt financing contingencies from PRN reduces uncertainty in the transaction.
• The secured promissory note provides immediate working capital to NovaBay.
• The equity funding commitment letter from RoundTable Healthcare Partners provides assurance of PRN's ability to complete the transaction.
• The Board's decision to proceed with the PRN transaction indicates confidence in the deal.

Negatives

• The company ended its engagement with Refresh, potentially missing out on a better offer.
• The transaction is still subject to stockholder approval, which introduces some uncertainty.
• The promissory note is secured by all of the company's assets, which could be a risk if the transaction does not close.

Risks

• The transaction is subject to stockholder approval, which may not be obtained.
• The Bridge Loan is secured by all of the company's assets, which could be a risk if the transaction does not close.
• There is a risk that the transaction may not close by the outside date of February 28, 2025.
• The company is subject to risks detailed in its SEC filings, which could cause results to differ materially from forward-looking statements.

Future Outlook

The company intends to provide its stockholders with additional supplemental disclosure to the definitive proxy statement and will file relevant materials with the SEC. The company is focused on obtaining stockholder approval for the transaction with PRN and the potential voluntary liquidation and dissolution of the company.

Management Comments

• We are pleased to accept PRNs revised offer for the Avenova brand and continue our efforts to obtain stockholder approval.
• With the newly added value, we truly believe this deal is in the best interests of our stockholders.

Industry Context

This announcement reflects the ongoing consolidation and deal-making activity in the pharmaceutical and healthcare sectors. The revised offer and the company's decision to proceed with PRN over Refresh indicate a strategic focus on maximizing value for shareholders in a competitive market.

Comparison to Industry Standards

• The increase in purchase price from $9.5 million to $11.5 million represents a 21% increase, which is a significant improvement for NovaBay shareholders.
• The inclusion of a bridge loan and equity funding commitment from PRN demonstrates a strong commitment to the transaction and provides financial stability for NovaBay during the transition.
• The decision to end engagement with Refresh after receiving a superior offer from PRN suggests that the company is prioritizing a deal with a higher degree of certainty and financial backing.
• The use of a secured promissory note is a common practice in M&A transactions to provide short-term financing and bridge the gap until the deal closes.

Stakeholder Impact

• Shareholders will benefit from the increased purchase price of $11.5 million.
• Employees of the eyecare business may be affected by the transaction, but the document does not provide details.
• Customers of Avenova will likely see a change in ownership of the brand.
• Creditors of NovaBay may be impacted by the transaction, but the document does not provide details.

Next Steps

• NovaBay will file the full text of the Amendment and the Bridge Loan with the SEC.
• NovaBay will provide stockholders with additional supplemental disclosure to the Special Meeting Proxy Statement.
• NovaBay will hold the Special Meeting of stockholders on November 22, 2024, to approve the transaction with PRN.
• The company will continue to work towards closing the transaction with PRN.

Key Dates

Keywords

Asset Purchase Agreement, PRN Physician Recommended Nutriceuticals, Avenova, eyecare business, acquisition, stockholder approval, Bridge Loan, equity funding, superior proposal, Refresh Acquisitions BidCo LLC